Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sabatolimab (MBG453) +/- Spartalizumab in Advanced Malignancies
NCT02608268Phase 2Terminated
- Sponsor
- Novartis
- Start
- Nov 2015
- Primary completion
- Aug 2022
- Modality
- Monoclonal Antibodies
- Countries
- 9
01
Overview
A Phase 2 trial of sabatolimab in solid tumor (advanced stage), melanoma, non-small cell lung carcinoma (NSCLC), renal cell carcinoma (RCC), sponsored by Novartis. Started Nov 2015; status: terminated.
02
Drugs
sabatolimab
03
Conditions
solid tumor (advanced stage)melanomanon-small cell lung carcinoma (NSCLC)renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT02608268.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02608268.